Skip to content

Mallesons Pulse Blog

  • Topics
    • All Topics
    • Carbon markets
    • Competition & consumer
    • Consumer protection
    • ESG
    • Future energy
    • Hydrogen
    • Inhouse Counsel
    • International Arbitration
    • Intellectual Property
    • Technology
  • Jurisdictions
    • Australia
    • China
    • Hong Kong
    • Singapore
    • Global
  • Specialty Blogs
    • In Competition
    • IP Whiteboard
  • Authors

Mallesons Pulse Blog

  • Topics
    • All Topics
    • Carbon markets
    • Competition & consumer
    • Consumer protection
    • ESG
    • Future energy
    • Hydrogen
    • Inhouse Counsel
    • International Arbitration
    • Intellectual Property
    • Technology
  • Jurisdictions
    • Australia
    • China
    • Hong Kong
    • Singapore
    • Global
  • Specialty Blogs
    • In Competition
    • IP Whiteboard
  • Authors

Aripiprazole

Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent)

Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent)

26 August 2016
By Suzy Madar
On Wednesday the Full Court of the Federal Court of Australia handed down a decision in which it upheld Justice Yates’ findings that Otsuka’s patent relating to aripiprazole, a drug used in the treatment of schizophrenia, is invalid for want of novelty and inventive step. 
Read on

Speciality blogs

  • In Competition
  • IP Whiteboard

More from IP Whiteboard

  • IP Whiteboard

Trending topics

  • Dispute resolution & litigation
  • Hong Kong
  • Litigation
  • Technology
View All Topics

Most viewed

ASIC flexes muscles in scam and phishing takedowns

Read More
Mallesons
©2026 Mallesons
Terms of use & legal notices | Privacy statement

Follow us

  • LinkedIn
Subscribe to Mallesons Pulse
©2026 Mallesons